

## Quality indicators of screen-detected breast cancer diagnosis and treatment in Italy and impact of specialization

Copenhagen - June 5<sup>th</sup>, 2008

**Antonio Ponti**  
CPO Piemonte, Torino (Italy)



**This presentation is dedicated to**

**Vito Distante, MD  
Professor of Surgery, Florence**

**Leader of QT Survey  
President of Italian Screening Network**

# # of screening programs and # of cases

## Italian screening programmes, QT Survey



# Italian screening programmes, QT Survey



Valle d'Aosta

Piemonte

Veneto

Emilia Romagna

Toscana

Lazio

2000-2006

Lombardia (Brescia)


Umbria

Campania

Puglia (Lecce)

Sicilia

At least one year



# National Clinical Audit of Screen-detected Breast Cancer



**NHS**

**Cancer Screening Programmes**

**NHS BREAST SCREENING PROGRAMME**  
**&**  
**ASSOCIATION OF BREAST SURGERY  
AT BASO**

**AN AUDIT OF SCREEN DETECTED BREAST CANCERS  
FOR THE YEAR OF SCREENING  
APRIL 2005 TO MARCH 2006**

*DISTRIBUTED AT THE  
ASSOCIATION OF BREAST SURGERY AT BASO CONFERENCE*  
*23rd MAY 2007*

**NATIONAL MOTORCYCLE MUSEUM, BIRMINGHAM**

**West Midlands  
Cancer Intelligence Unit**

**Epidemiologia & Prevenzione**  
Rivista dell'Associazione Italiana di Epidemiologia  
ANNO 30 (1) GENNAIO-FEBBRAIO 2006 SUPPLEMENTO 3

**1976 - 2006  
E&P  
30 anni**

**The National Centre  
for Screening Monitoring  
Fifth Report**

**ccm**  
MINISTERO DELLA SALUTE  
CENTRO NAZIONALE PER LA PREVENZIONE  
E IL CONTROLLO DELLE MALATTIE

**CONFERENZA DEI PRESIDENTI DELLE  
REGIONI E DELLE PROVINCE AUTONOME**

**OSSERVATORIO  
NAZIONALE  
SCREENING**

**Lega Italiana  
per la Lotta  
contro i Tumori**

**GISC**  
GRUPPO ITALIANO  
SCEENING  
COLORETTECA

**GISCOR**  
GRUPPO ITALIANO  
SCREENING  
COLONOCOLORECTALE

**GIS**  
GRUPPO ITALIANO  
SCREENING  
MAMMOGRAPHICO

**i**  
Inferenze


**Foreword D. Greco 3**  
**Introduction M. Zappa, M. Rosselli Del Turco 5**  
**Mammography screening in Italy: 2003-2004 survey 7**  
*D. Giorgi, L. Giordano, L. Ventura, D. Puliti,  
P. Piccini, E. Paci*  
**Time trends of some indicators of mammography  
screening programmes in Italy, 1996-2003 17**  
*L. Giordano, D. Giorgi, P. Piccini, V. Stefanini,  
R. Castagnino, C. Senore*  
**Activity level and process indicators of organised  
programmes for cervical cancer screening in Italy 27**  
*G. Ronco, P. Giubilato, C. Naldoni, M. Zorzi,  
E. Anghinoni, A. Scalisi, P. Dalla Palma, L. Zanier,  
A. Federici, G. Angelini, S. Prandini, R. Magistretti,  
E. Marconi, R. Pizzati, A. Jossa, N. Segnani, M. Zappa*  
**Screening for colorectal cancer in Italy: 2004 survey 41**  
*M. Zorzi, G. Grazzini, C. Senore, M. Vettorazzi*  
**National Survey of the quality of second level  
screening for cervical cancer 51**  
*R. Volante, G. Ronco*  
**Audit system on Quality of breast cancer diagnosis  
and Treatment (OT): results from the survey  
on screen-detected lesions in Italy, 2003-2004 59**  
*A. Ponzi, M. P. Mano, V. Distante, M. Taffurelli,  
C. Naldoni, F. Zangriolami, M. Vettorazzi, M. Zorzi,  
G. Pagano, A. Federici, D. Baiocchi, R. Bordon,  
M. Tomatis, P. Martellini, L. Cataliotti,  
M. Rosselli Del Turco, N. Segnani*



# Italian screening programmes, QT Survey






## Pre-operative (C5/B5) diagnosis (n=16670)



# Pre-operative (B5/C5) diagnosis

## Italian programmes, range: 22,2% - 97,4%






**Figure 5: Variation in non-operative diagnosis rate with screening unit, expressed as a proportion of cancers detected in each screening unit**

# Italian screening programmes, QT Survey




**Clear margins  $\leq 1\text{mm}$ . at final intervention (n=14711)**




# Italian screening programmes, QT Survey



## Breast conservation surgery in pT1 cases (n=10302)




# Conservative surgery in pT1 ca (2006, N=1679)




# Italian screening programmes, QT Survey



## Conservation surgery in DCIS (N=2090)



## Conservation surgery in DCIS (2006, N=390)



## **Conservation surgery in DCIS**

**UK**

**BCS in SD cases**



**2005-2006**

**Ages 50-69**

**68% (n=3122)**

---

---

**Australia, National Breast Screening Audit**

**BCS, all cases**

**1998-2004**

**Ages 50-69**


**50.4% (n=3629)**

# Italian screening programmes, QT Survey



OSSERVATORIO  
NAZIONALE  
SCREENING

## Immediate reconstruction (N=2545)




# Italian screening programmes, QT Survey




## Immediate reconstruction after mastectomy

(2006: N=447, 30% missing)




## Use of sentinel lymphnode (SLN) technique



# Italian screening programmes, QT Survey




## pN0 (inv.) with SLN only (N=1539)




# Italian screening programmes, QT Survey



## pN0 with SLN only (N=1539)




## Axillary clearance in DCIS (N=2090)



# Italian screening programmes, QT Survey




## SLN in DCIS grade I,II (N=1210)



# Italian screening programmes, QT Survey




## Sentinel lymphnode in benign lesions



\* 16 benign lesions excluded because B5

# Italian screening programmes


## B/M ratio time trend



# Italian screening programmes, QT Survey





**Operation within 60 days after screening mammogram (n=15129)**



# Surgery within 90 days from screening

Range: 48,4% - 100%



# **Is Mode of Breast Cancer Detection Associated With Cancer Treatment in the United States?**

**K. Robin Yabroff, PhD, MBA<sup>1</sup>**

**Linda C. Harlan, PhD, MPH<sup>1</sup>**

**Limin X. Clegg, PhD<sup>1,2</sup>**

**Rachel Ballard-Barbash, MD, MPH<sup>1</sup>**

**Jennifer Stevens, BS<sup>3</sup>**

**Donald L. Weaver, MD<sup>4</sup>**

<sup>1</sup> Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland.

<sup>2</sup> Office of Healthcare Inspections, Office of Inspector General, U.S. Department of Veterans Affairs, Washington, District of Columbia.

<sup>3</sup> Information Management Services, Inc., Silver Spring, Maryland.


<sup>4</sup> Department of Pathology, University of Vermont College of Medicine, Burlington, Vermont.

**TABLE 2**  
**Treatment by Mode of Breast Cancer Detection**

Variable	Mode of detection*				Chi-square (P)
	Mammography		Other		
	No.	%	No.	%	
Receipt of guideline-consistent primary and adjuvant treatment <sup>†</sup>					
Yes	229	48.7	250	56.8	6.0 (.015)
No	241	51.3	178	43.2	

# Population study in Piedmont on impact of mode of detection and specialization on breast cancer care


---



## Mode of detection

<b>Screening program mammography</b>	<b>444 (40.7%)</b>
<b>Spontaneous mammography</b>	<b>222 (20.3%)</b>
<b>Signs or symptoms</b>	<b>380 (34.8%)</b>
<b>Missing</b>	<b>46 (4.2%)</b>
<b>TOTAL</b>	<b>1082 (100.0%)</b>

## Distribution by mode of detection and volume of cases of treating Unit



# Piedmont, population sample 2002/2004

## Pre-operative diagnosis B5/C5

(missing 10.1%)

Volume	N.Tot.	%	OR	C.I. 95%
< 50	<b>237</b>	<b>53,6</b>	<b>1</b>	-
50 - 149	<b>441</b>	<b>59,0</b>	<b>1,28</b>	0,93 – 1,76
≥ 150	<b>306</b>	<b>72,2</b>	<b>2,26</b>	1,57 – 3,25

Adjusted by age, education, screening detection.

# Piedmont, population sample 2002/2004

## Pre-operative diagnosis B5/C5

(missing 10.1%)

Mode of detection	N.Tot.	%	OR	C.I. 95%
Other	<b>541</b>	<b>61,0</b>	<b>1</b>	-
Screen Detected	<b>440</b>	<b>63,4</b>	<b>1,16</b>	0,88-1,54

Adjusted by age, education, volume of treating hospital.

# Piedmont, population sample 2002/2004

## Conservation surgery in pT1 cases

Volume	N.Tot.	%	OR	C.I. 95%
< 50	132	90,9	1	-
50 - 149	249	90,4	1,01	0,49 – 2,09
≥ 150	150	87,3	0,73	0,34 – 1,58

Adjusted by age, education, screening detection.

# Piedmont, population sample 2002/2004

## Conservation surgery in pT1 cases

(missing 0%)

Mode of detection	N.Tot.	%	OR	C.I. 95%
Other	265	88.6	1	
Screen Detected	250	90.8	1.29	0.72-2.34

Adjusted by age, education, volume of treating hospital.

# Piedmont, population sample 2002/2004

## Sentinel lymphnode in invasive cases

(missing 2.1%)

Volume	N.Tot.	%	OR	C.I. 95%
< 50	234	30,3	1	-
50 - 149	437	37,9	1,31	0,92 – 1,87
≥ 150	254	53,5	2,40	1,61 – 3,55

Adjusted by age, education, screening detection.

# Piedmont, population sample 2002/2004

## Sentinel lymphnode in invasive cases

(missing 2.1%)

Mode of detection	N.Tot.	%	OR	C.I. 95%
Other	<b>551</b>	<b>32.8</b>	<b>1</b>	
Screen Detected	<b>355</b>	<b>52.9</b>	<b>1.79</b>	1.33-2.43

Adjusted by age, education, volume of treating hospital.

# Piedmont, population sample 2002/2004

## DCIS (grade I,II) with sentinel lymphnode

(missing 0.8%)

Volume	N.Tot.	%	OR	C.I. 95%
< 50	16	12,5	1	-
50 - 149	46	20,4	1,44	0,34 – 6,15
≥ 150	58	32,1	2,32	0,59 – 9,16

Adjusted by age, education, screening detection.

# Piedmont, population sample 2002/2004

## DCIS (grade I,II) with sentinel lymphnode

(missing 0.8%)

Mode of detection	N.Tot.	%	OR	C.I. 95%
Other	46	30.4	1	
Screen Detected	73	17.3	0.45	0.17-1.16

Adjusted by age, education, volume of treating hospital.


# **Conclusions**

**Screening may positively influence quality of breast cancer care, by**


- Referral of SD cases to specialist Breast Units**
- Encouraging monitoring of performance parameters and Clinical Audit.**

# Italian screening programmes, QT Survey

## Histological diagnosis of SD lesions



B/M = 0.16




Italy, Screening Network – QT Survey 2005-2006

\* Sum is less than 881 because synchronous lesions have been excluded from the pie

# Italian screening programmes, QT Survey

## Benign histological type




Normal tissue	5,3%	45
Fibroadenoma	15,2%	129
Cysts	3,2%	27
Apocrine metaplasia	0,7%	6
Fibrocystic mastopathy	14,9%	126
Schlerosing adenosis	12,0%	102
Atypical lobular hyperplasia	1,4%	12
Benign phylloid tumour	1,3%	11
Atypical ductal hyperplasia	15,6%	132
Radial scar	3,2%	27
Papilloma/papillomatosis	14,0%	119
Other	9,6%	81
Unknown	3,5%	30

Italy, Screening Network – QT Survey 2005-2006


# Specimen to Tumour Volume Ratio

## Factors Influencing Outcomes for Breast Conservation Therapy of Mammographically Detected Malignancies

Valerie L Staradub, MD, Alfred W Rademaker, PhD, Monica Morrow, MD, FACS



$$\text{STVR} = \frac{\text{Volume pezzo asportato}}{\text{Volume lesione}} = \frac{\text{Large Gray Circle}}{\text{Small Pink Tumor}}$$



# Mean log(STVR) by histological type

243 screening benign lesions 2005-2006

